Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
Department of Medicine, Division of Dermatology, University of Louisville, Louisville, KY, USA.
Courtney S
CS
Woodmansee
Michael W
MW
McCall
D000368:Aged; D000634:Aminoquinolines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy* / Q000473:pathology; D000077271:Imiquimod; D008297:Male; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod